Clinical Trial Detail

NCT ID NCT02422381
Title MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Providence Health & Services
Indications

lung non-small cell carcinoma

Therapies

Gemcitabine

Pembrolizumab

Age Groups: adult

No variant requirements are available.